Ipsen and IRLAB have signed a licensing agreement, providing Ipsen exclusive worldwide development and commercial rights to mesdopetam, a novel dopamine D3-receptor antagonist. “We are excited to enter this licensing

Amniotics, a stem cell therapy company, has raised SEK 60 million through its recent listing on Nasdaq First North Growth Market. The offering was fully subscribed and attracted widespread interest

Bio-Me has raised NOK 10 million in a fully subscribed funding round. Both existing and new investors participated in the financing round, with new investors contributing the majority of the

Xbrane has carried out a directed share issue of SEK 380 millions at a subscription price of SEK 135 per share. The subscription price was determined through an accelerated book-building

The company has received Advanced Therapy Medicinal Product (ATMP) classification from the European Medicines Agency (EMA) for the company’s lead cancer relapse vaccine candidate, DCP-001. DCP-001 is derived from Immunicum’s

BioArctic’s partner Eisai has announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for lecanemab (BAN2401). BAN2401 is an investigational anti-amyloid beta (Aβ) protofibril antibody

The company has announced two exclusive license agreements with The University of Texas MD Anderson Cancer Center related to MAGE-A4 and VGLL1 targeting allogeneic “off-the-shelf” TCR-NK cell therapies for the

Elicera Therapeutics has announced that the subscription period for the company’s new share issue prior to the planned listing on Nasdaq First North Growth Market began May 24 and runs

The board of directors of Lytix Biopharma has decided to apply for a listing of the company on Euronext Growth, simultaneously carrying out a capital increase. Lytix Biopharma has decided

Xbrane announces ambition to generate positive operating cash flow monthly by late 2023/early 2024 and to initiate one new biosimilar development program per annum. Xbrane is on track towards regulatory